SEC Form 4 · accession 0001179110-16-030448
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew John Nichols
Officer — Chief Scientific Officer
Period of report
Oct 3, 2016
Accepted (ET)
Oct 5, 2016 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.79 | Oct 3, 2016 | A | 13,000 | A | — | Oct 2, 2026 | Common Stock | 13,000 | 13,000 | D |
Explanation of responses
- F1This option was granted on October 3, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of October 1, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.